A Phase II Study of Venetoclax (ABT-199) Added to Ibrutinib in Patients With High-Risk Chronic Lymphocytic Leukemia (CLL)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 28 Aug 2017
At a glance
- Drugs Venetoclax (Primary) ; Allopurinol; Ibrutinib
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 24 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 16 Jun 2017 Status changed from not yet recruiting to recruiting.
- 28 Apr 2017 New trial record